Fluzone High-Dose

BIOLOGICAL5 trials

Sponsors

Mount Sinai Hospital, Canada, Mayo Clinic, Centers for Disease Control and Prevention, University of Alabama at Birmingham, The University of Hong Kong

Conditions

Influenza

Phase 1

A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV

CompletedNCT02263040

Mount Sinai Hospital, CanadaInfluenza

Start: 2014-10-31End: 2016-12-31Updated: 2019-01-28

Phase 3

Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients

The University of Hong KongInfluenza

Start: 2019-10-23End: 2023-03-31Target: 4000Updated: 2021-04-28

Phase 4

Gene Signatures of Influenza Vaccine Responses in Older Adults

CompletedNCT03603509

Mayo ClinicInfluenza

Start: 2018-08-27End: 2019-01-02Updated: 2023-05-16

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

CompletedNCT03722589

Centers for Disease Control and PreventionInfluenza

Start: 2018-09-12End: 2020-07-31Updated: 2024-07-22

B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults

RecruitingNCT04101838

University of Alabama at BirminghamInfluenza

Start: 2021-04-01End: 2026-05-31Target: 50Updated: 2025-09-17

Related Papers

Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines.

2024-01-0414 citations

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized, Open-Label Trial

Clinical Infectious Diseases2022-08-2914 citations

Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18–64 Years: A Randomized Open-Label Trial

Clinical Infectious Diseases2021-06-2441 citations